Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of hormone replacement therapies on postprandial lipids and glucose
2015-002326-39Phase 4Terminated
- Sponsor
- Regionshospitalet Herning
- Start
- May 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of estradiol, raloxifene, tibolone, estradiol + norethindrone and Placebo-COD Research Private Ltd in menopause (4 arms), sponsored by Regionshospitalet Herning. Primary endpoints: Postprandial area under the curve for total cholesterol, Postprandial area under the curve for HDL cholesterol and 3 more. Started May 2015; status: terminated.
02
Drugs
estradiolraloxifenetiboloneestradiol + norethindronePlacebo-COD Research Private Ltd
03
Conditions
menopause
Beyond the preview
Go deeper on 2015-002326-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002326-39.